GSK PLC Faces Investigation Over Asthma Inhaler Discontinuation

In a significant development, GSK PLC, a leading research-based pharmaceutical company, is under investigation by U.S. Senator Maggie Hassan. The probe centers on the company’s decision to discontinue a widely used asthma inhaler for children, known as Flovent Asthmealer. Senator Hassan has accused GSK of rebranding the inhaler to avoid a substantial $367 million Medicaid rebate, as reported by multiple sources including Benzinga, Seeking Alpha, and Reuters.

The investigation highlights concerns over the impact of this decision on children’s access to essential asthma medication. GSK, which operates primarily in the Health Care sector and is listed on the London Stock Exchange, has been a key player in developing and marketing a range of pharmaceutical products, including vaccines and medicines for various conditions such as asthma.

GSK Announces Price Reduction for Malaria Vaccine

In a separate development, GSK, in collaboration with Bharat Biotech International Ltd, has committed to significantly reducing the price of the world’s first malaria vaccine, RTS,S. The companies have pledged to lower the cost to less than $5 per dose by 2028, more than halving its current price. This initiative aims to improve access to the vaccine in malaria-endemic regions, particularly for children.

GSK’s Financial and Corporate Updates

GSK Capital B.V. has published its 2024 annual report and financial statements, providing insights into the company’s financial health and strategic direction. Additionally, GSK has engaged in transactions involving its own shares, as noted in reports from Research Tree.

Regulatory Approvals and Industry Engagement

The U.S. FDA has approved GSK’s Benlysta autoinjector for the treatment of lupus nephritis, expanding the company’s portfolio of approved treatments. Furthermore, GSK has been actively participating in industry discussions, including honoring 2025 LGBTQ+ Pride month alongside other major pharmaceutical companies.

Market Performance

As of June 25, 2025, GSK’s share price closed at 1405.5 GBP, with a 52-week high of 1678.68 GBP and a low of 1242.5 GBP. The company’s market capitalization stands at 58.73 billion GBP, with a price-to-earnings ratio of 18.82.

These developments reflect GSK’s ongoing efforts to address public health challenges while navigating regulatory and market dynamics. For more detailed information, stakeholders can visit GSK’s official website at www.gsk.com .